



These additions and changes are effective 8/16/24

Pharmacy Benefit Additions (these apply to Exchange only):

Agamree (vamorolone) – Pharmacy benefit, Non-Preferred brand, PA

Bosulif (bosutinib) capsules – Pharmacy benefit, Non-Preferred brand, PA

Eohilia (budesonide) – Pharmacy benefit, Non-Formulary

Generic Gralise (gabapentin ER) – Pharmacy benefit, Non-Formulary

Penbraya (meningococcal ACYW (tet conj)-mening b (rcmb) vacc) – Pharmacy benefit, \$0 ACA Preventative

Wainua (eplontersen) – Pharmacy benefit, Non-Preferred brand, PA and QL of 1 syringe per 30 days

Iwilfin (eflornithine) – Pharmacy benefit, Non-Preferred brand, PA

Zilbrysq (zilucoplan) – Pharmacy benefit, Non-Preferred brand, PA

ZITUVIO (sitagliptin) – Pharmacy benefit, Non-Formulary

Pharmacy Benefit Changes (these apply to Exchange only):

Adbry (tralokinumab-ldrm) – Pharmacy benefit, age update

Dupixent (dupilumab) – Pharmacy benefit, Age and weight update

Tarpeyo (budesonide) – Pharmacy benefit, criteria updates

Wegovy (semaglutide) – Pharmacy benefit, New Indication, Reduce the risk of major adverse cardiovascular events

Medical Benefit Additions/Changes (these apply to Medicare and Exchange):

Combogesic Inj (acetaminophen and ibuprofen) – Medical benefit, Non-Formulary

Besponsa (inotuzumab ozogamicin) – Medical benefit, new indication, on PSCE

Keytruda (pembrolizumab) – Medical benefit, new indication

Onivyde (irinotecan liposome injection) – Medical benefit, new indication

Opdivo (nivolumab) – Medical benefit, new indication

Reblozyl (luspatercept-aamt) – Medical benefit, new indication